Volume 5, Issue 11: Newly Approved Pangenotypic HCV Therapies
e-Viral Hepatitis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with Hepatitis. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.
(Volume 5, Issue 11)
Nurses and health care professionals involved in the care of patients with Hepatitis.
After participating in this activity, the participant will demonstrate the ability to:
- Describe the appropriate use of the sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) regimen in retreatment of prior HCV treatment failures.
- Describe the appropriate use of the glecaprevir/pibrentasvir (GLE/PIB) regimen across HCV genotypes in treatment-naïve and treatment-experienced patients with or without cirrhosis.
- Describe the appropriate use of each of GLE/PIB in the treatment of HCV infection in patients with renal disease.
Director of Hepatology
New York University School of
New York, NY
- 1.00 ANCC
- 1.00 Attendance